CoChat
Sign Up
Cited by 369Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and LipoproteinsDrug-Induced Hepatotoxicity and Protection

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H., Perrillo, R. P.·2004·Alimentary Pharmacology & Therapeutics
DOI 10.1111/j.1365-2036.2004.02025.x
Open this paper in CoChat — free account

Abstract

BACKGROUND: Insulin sensitizing agents may be useful in treatment of non-alcoholic fatty liver disease. AIM: A pilot study to evaluate the efficacy and safety of metformin in non-alcoholic fatty liver disease. METHODS: In an open labelled study, patients with histologically confirmed non-alcoholic fatty liver disease were given metformin (20 mg/kg) for 1 year. Insulin resistance (by log homeostasis assessment model analysis for insulin resistance and Quantitative Insulin Sensitivity Check Index) and post-treatment hepatic histology were compared with pre-treatment histology. RESULTS: Fifteen patients completed 1 year of treatment. During the initial 3 months, there was improvement in alanine aminotransferase and aspartate aminotransferase (P-value 0.01 and 0.02, respectively) along with improvement in insulin sensitivity. However, after 3 months, there was no further improvement in insulin sensitivity and there was gradual rise in aspartate aminotransferase and alanine aminotransferase back to pre-treatment levels. Among the 10 patients with post-treatment biopsy, three (33%), showed improvement in steatosis, two (20%) showed improvement in inflammation score and one (10%) showed improvement in fibrosis. CONCLUSION: Metformin treatment was associated with only a transient improvement in liver chemistries. A progressive, sustainable reduction in insulin sensitivity was not noted during treatment.

Overview

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2004.02025.x

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Research works printed but not linked: 1

  1. 10.1002/hep.1840380427 · DOI

Cited by

Sorted by citations

Items 301–366 of 366

Related

See all

Metadata

Authors
Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H., & Perrillo, R. P.
Affiliations
  • Ochsner Medical Center (US)
  • Johns Hopkins University (US)
Corresponding author
Nair, S.
ORCID
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2004-06-14
Volume
20
Issue
1
Pages
23-28
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
DOI
10.1111/j.1365-2036.2004.02025.x
OpenAlex
W2056505063
Cited by
369
References
37
Citations by year
2026: 1 · 2025: 3 · 2024: 13 · 2023: 13 · 2022: 7 · 2021: 10 · 2020: 9 · 2019: 6 · 2018: 14 · 2017: 13 · 2016: 9 · 2015: 22 · 2014: 21 · 2013: 21 · 2012: 17
FWCI
20.68
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Alimentary Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
metformin, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, insulin sensitizers, insulin resistance, HOMA-IR, QUICKI, hepatic steatosis, liver fibrosis, liver inflammation, alanine aminotransferase, aspartate aminotransferase, drug safety and efficacy
MeSH terms
Alanine Transaminase, Aspartate Aminotransferases, Drug Evaluation, Female, Hepatitis, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Metformin, Middle Aged, Patient Compliance, Pilot Projects, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review